354 related articles for article (PubMed ID: 24566314)
1. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
2. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
3. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors.
Malczewska A; Kidd M; Matar S; Kos-Kudla B; Modlin IM
Neuroendocrinology; 2018; 107(1):73-90. PubMed ID: 29566385
[TBL] [Abstract][Full Text] [Related]
5. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.
Kawasaki K; Fujii M; Sato T
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29590641
[TBL] [Abstract][Full Text] [Related]
7. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
Milione M
Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
[No Abstract] [Full Text] [Related]
9. Sensitivity and Specificity of the NETest: A Validation Study.
Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J
Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
11. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
12. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
[TBL] [Abstract][Full Text] [Related]
13. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors.
Chen P; Wang Q; Xie J; Kwok HF
Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326
[TBL] [Abstract][Full Text] [Related]
14. Gastroenteropancreatic endocrine tumors.
Meeker A; Heaphy C
Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
[TBL] [Abstract][Full Text] [Related]
15. A novel germline mutation at exon 10 of MEN1 gene: a clinical survey and positive genotype-phenotype analysis of a MEN1 Italian family, including monozygotic twins.
Palermo A; Capoluongo E; Del Toro R; Manfrini S; Pozzilli P; Maggi D; Defeudis G; Pantano F; Coppola R; Di Matteo FM; Raffaelli M; Concolino P; Falchetti A
Hormones (Athens); 2018 Sep; 17(3):427-435. PubMed ID: 30083881
[TBL] [Abstract][Full Text] [Related]
16. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
[TBL] [Abstract][Full Text] [Related]
17. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
[TBL] [Abstract][Full Text] [Related]
18. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
[TBL] [Abstract][Full Text] [Related]
19. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiles distinguish different subtypes of gastroenteropancreatic neuroendocrine tumors.
How-Kit A; Dejeux E; Dousset B; Renault V; Baudry M; Terris B; Tost J
Epigenomics; 2015; 7(8):1245-58. PubMed ID: 26360914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
